Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,674,619
  • Shares Outstanding, K 61,695
  • Annual Sales, $ 393,500 K
  • Annual Income, $ -409,120 K
  • EBIT $ -155 M
  • EBITDA $ -136 M
  • 60-Month Beta 0.45
  • Price/Sales 32.70
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 44.15% (+1.64%)
  • Historical Volatility 35.49%
  • IV Percentile 38%
  • IV Rank 25.01%
  • IV High 70.31% on 08/01/25
  • IV Low 35.43% on 12/11/24
  • Expected Move (DTE 11) 10.26 (4.99%)
  • Put/Call Vol Ratio 0.32
  • Today's Volume 704
  • Volume Avg (30-Day) 984
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 17,579
  • Open Int (30-Day) 13,163
  • Expected Range 195.18 to 215.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.20
  • Number of Estimates 7
  • High Estimate 0.34
  • Low Estimate 0.11
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +129.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
188.07 +9.24%
on 11/13/25
223.18 -7.95%
on 11/17/25
+7.69 (+3.89%)
since 11/05/25
3-Month
186.05 +10.42%
on 10/20/25
223.18 -7.95%
on 11/17/25
-0.47 (-0.23%)
since 09/05/25
52-Week
118.03 +74.06%
on 02/12/25
223.18 -7.95%
on 11/17/25
+73.37 (+55.55%)
since 12/05/24

Most Recent Stories

More News
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

–  Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today...

ASND : 205.44 (-1.51%)
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial...

ASND : 205.44 (-1.51%)
Ascendis Pharma Reports Third Quarter 2025 Financial Results

–   Q3 2025 revenue of €143.1 million for YORVIPATH ® and €50.7 million for SKYTROFA ® –   Q3 2025 operating profit of €11.0 million –   TransCon ® CNP (navepegritide)...

ASND : 205.44 (-1.51%)
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function...

ASND : 205.44 (-1.51%)
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday,...

ASND : 205.44 (-1.51%)
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine...

ASND : 205.44 (-1.51%)
Ascendis Pharma Grants Employee Warrants to Boost Engagement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ascendis...

ASND : 205.44 (-1.51%)
Ascendis Pharma (ASND) Receives a Buy from Morgan Stanley

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ascendis Pharma today and set a price target of $250.00. The company’s shares opened today at $214.06.Elevate Your Investing Strategy: Take...

ASND : 205.44 (-1.51%)
J.P. Morgan Sticks to Its Buy Rating for Ascendis Pharma (ASND)

In a report released today, Jessica Fye from J.P. Morgan maintained a Buy rating on Ascendis Pharma, with a price target of $264.00. The company’s shares opened today at $210.00.Elevate Your Investing...

ASND : 205.44 (-1.51%)
Ascendis Pharma Submits EMA Application for Achondroplasia Treatment

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ascendis...

ASND : 205.44 (-1.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 217.04
2nd Resistance Point 214.52
1st Resistance Point 209.98
Last Price 205.44
1st Support Level 202.92
2nd Support Level 200.40
3rd Support Level 195.86

See More

52-Week High 223.18
Last Price 205.44
Fibonacci 61.8% 183.02
Fibonacci 50% 170.61
Fibonacci 38.2% 158.20
52-Week Low 118.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar